NCI-Sponsored Clinical Trials Andrea Denicoff, RN, MS, ANP 1 Worta McCaskill-Stevens, MD 2 Jo Anne Zujewski, MD 1 Jeff Abrams, MD 1 June 25, 2007 NCCCP.

Slides:



Advertisements
Similar presentations
MMC Cancer Institute Navigation Program Donna Green BSN, RN,BA,OCN
Advertisements

1 NCORP Overview November 2013 NCORP Director Worta McCaskill-Stevens, MD, MS Chief, Community Oncology and Prevention Trials Research Group Division of.
1 LeTourneau University Tim Ochran, MS, DABR, Associate Professor of Radiation Oncology, UTHSCT January 26, 2011.
PLENARY SESSION Fall Group Meeting Miami, FL November 13, 2010.
 Meeting the needs of cancer survivors across the lifespan Norton Cancer Institute Survivorship Program Christy Roberts, RN, BSN, OCN.
Guideline for Monitoring of Clinical Trials for Cooperative Groups, CCOP Research Bases, and the Clinical Trials Support Unit (CTSU) Lore Lagrone Program.
Advocating for Clinical Trial Accural
ACRIN Presentation Cancer Trials Support Unit Basics September 21, 2011 Martha Hering, RN, CCRP 21 Sept ACRIN Presentation.
Implementation of the Navigator Role in Community – Based Oncology Program Our Journey Joan M. Daugherty, RN, MS Executive Director, Richard A. Henson.
TAXOL® (paclitaxel) for Adjuvant Treatment of Node Positive Breast Cancer Oncologic Drugs Advisory Committee September 17, 1999.
Hematology/Oncology Fellowship Kristie A. Blum, M.D. Gregory Otterson, M.D. The Ohio State University Department of Medicine, Division of Hematology &
Todays Clinical Trials. Tomorrow’s Cures. Robert L. Comis, MD 1 National Coalition for Cancer Research “Cancer 101” Congressional Briefing 09/10/14.
Cancer Clinical Trials:
St. Joseph Hospital Cancer Center & Cancer Institute NCCCP Pilot Project.
A New Point of View: An “Outsider’s” Perspective From the Inside of the NCI and the CCOP Strategic Plan Marge Good, RN, BSN, MPH, OCN MD Anderson Cancer.
Cancer Center Trials at St. Barnabas Medical Center.
Welcome to the Fall 2010 TBPT Meeting Dr. Paul Klotman President and CEO Baylor College of Medicine November 3, 2010.
Hartford Hospital Helen & Harry Gray Cancer Center, Hartford, Connecticut.
Norris Cotton Cancer Center Global Update CTOP RETREAT May 2014.
MS/AL Radiation Oncology Research Partnership W. Sam Dennis, MD, PhD P.I., Singing River Hospital System Sharon Spencer, MD P.I., University of Alabama.
CALGB Informational Session June 22, 2007 David Hurd, MD Interim Chair Data Audit Committee.
ACRIN Research Associates Educational Session Radiation Therapy Oncology Group Research Associates Committee Joyce Neading, RHIT, CTR Program Director,
Clinical Trials – An Academic Perspective Mohammed Milhem, MD University of Iowa.
Caveats We are interpreting the guidelines along with you We may have some limited additional insight due to participation during the course of planning.
Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate.
NCI Review of the Clinical Trials Process 6 th Annual National Forum on Biomedical Imaging in Oncology James H. Doroshow M.D. April 7, 2005 Bethesda, Maryland.
ODAC SCHERING-PLOUGH RESEARCH INSTITUTE 1 Temozolomide Oncology Drug Advisory Committee March 13, 2003 Craig L. Tendler, M.D. Vice President, Oncology.
1 Targeted Strategies to Improve Physician and Patient Access to Cancer Clinical Research An Overview of Coalition Programs and Services Ruth Lambersky.
NCI’s Cancer Information Service Program Mary Anne Bright Office of Cancer Information Service, NCI June 25, 2007.
Developing Relationships: Cooperative Group Networking Developing Relationships: Cooperative Group Networking Kandie Dempsey, MS, RN, OCN, CCRP Delaware.
BIOMEDICAL IMAGING PROGRAM NATIONAL CANCER INSTITUTE.
Connecting South Carolina: The Gibbs/Hollings Cancer Center An NCCCP/NCI Designated Center Connection Anita L. Harrison, MPH Associate Director, Administration.
1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients.
CCR Clinical Research Priorities Clinical research is an essential part of the CCR research program Translational (collaborative) Interaction between basic.
How can we work together? Partnering with Industry: An Investigator’s Perspective Robert L. Coleman, MD M. D. Anderson Cancer Center.
Sanford USD Medical Center Sioux Falls, SD Becky Nelson, Senior VP & COO Health Service Operations Sanford Health.
Minimum Standards and Exemplary Attributes of Clinical Trial Sites S. Gail Eckhardt, MD (Slides prepared by Robin Zon, MD)
Overview of NCI Supported Fatigue Trials Ann O’Mara, PhD, RN, FAAN.
The Cancer Trials Support Unit (CTSU) Steve Riordan, Project Director Jenny Hopkins, Task Manager CTSU/Westat, Rockville, MD June 26, 2007 Clinical Trials.
Chair:Dr. Vivien Bramwell NATIONAL CANCER INSTITUTE OF CANADA CLINICAL TRIALS GROUP Sarcoma Committee CANADIAN SARCOMA GROUP.
OEWG Kick-Off Meeting Meg Mooney, MD Chief, Clinical Investigations Branch CTEP, DCTD, NCI – March 24, 2010 CTEP & Cooperative Group Plans for OEWG Implementation:
Gynecologic Oncology Group Gynecologic Oncology Group (GOG) Sharon Stockman, C-CRC The University of Iowa Hospitals Iowa City, IA Chair, GOG Data Management.
Clinical Research in a Community Practice Bob Behrens, MD Iowa Oncology Research Association (IORA)
1 National Cancer Institute Clinical Trial Cooperative Groups Perspectives from the National Surgical Adjuvant Breast and Bowel Project Joyce Mull, MPM.
SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.
Cancer Centers In Clinical Trials Sandrine Marreaud Head of Medical Department.
ICTW Punta del Este, Uruguay Role of the Oncology Research Team.
James D. Bearden, III, MD, FACP Principle Investigator Gibbs Cancer Center, Spartanburg, SC Gibbs Cancer Center Our NCCCP Journey 1.
Andrea Denicoff, RN, MS, ANP Clinical Investigations Branch, CTEP, DCTD CTEP Program Meeting March 18, 2009 CTEP Phase III Cancer Treatment Trials with.
The SARC Sarcoma SPORE: A Unique Collaborative (Ad)venture Raphael E. Pollock, MD, PhD Department of Surgical Oncology Division of Surgery University of.
CDRP Program Steering Committee Dwight E. Heron, MD UPMC McKeesport February 2, 2007 Tampa, FL.
Enrollment and Monitoring Procedures for NCI Supported Clinical Trials Barry Anderson, MD, PhD Cancer Therapy Evaluation Program National Cancer Institute.
Robert H. Wiltrout Director, CCR Director’s Address.
Role of the Drug Project Team in Formulating the Initial Development Plan of NCI-IND agents Jeff Moscow, MD IDB, CTEP.
CDRP Program Update UPMC McKeesport Program Steering Committee RTOG Meeting Toronto, Canada June 23 rd, 2006.
CTEP Visiting Physician Externship Coordinator: Igor Espinoza-Delgado, M.D. NCI CTEP Investigational Drug Branch
AccrualNet: A New NCI Tool for Supporting Accrual to Clinical Trials Linda Parreco, RN, MS NCI, Office of Communication and Education September 29, 2010.
NJMS-UH Cancer Center Minority- Based Community Clinical Oncology Program.
NCCCP Pilot – Clinical Trials Ann O’Mara, PhD, RN, FAAN Program Director Community Clinical Oncology Program Division of Cancer Prevention June 26, 2007.
NCI Community Cancer Centers Program (NCCCP) Kate Castro, RN, MS, AOCN ® Nurse Consultant National Cancer Institute, Outcomes Research Branch Kate Castro,
S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.
11 Radiation Therapy Oncology Group Clinical Trials Administration Sharon Hartson Stine, Director Group Administrator.
ACOSOG Sarcoma Committee Chair: Peter W.T. Pisters, MD Vice Chairs: Edward Cheng, MD (Orthopedic Oncology) Robert Maki, MD, PhD (Medical Oncology) Brian.
National Cancer Institute
AACR Genomics In Clinical Medicine Think Tank
How to Navigate the NCTN and Participate in Imaging Research
Methods to Identify and Access Trials in Iowa
ICAS: CTOS 2005 Review of Studies
NRG Oncology Biospecimen Bank Report NRG Semiannual meeting
Presentation transcript:

NCI-Sponsored Clinical Trials Andrea Denicoff, RN, MS, ANP 1 Worta McCaskill-Stevens, MD 2 Jo Anne Zujewski, MD 1 Jeff Abrams, MD 1 June 25, 2007 NCCCP Launch 1 Division of Cancer Treatment & Diagnosis 2 Division of Cancer Prevention

Objectives Provide overview of NCI-sponsored clinical trials system Provide overview of clinical trials component of NCI Community Cancer Centers Program (NCCCP)

NCI-Sponsored Clinical Trials: Intramural & Extramural Intramural clinical trials – Conducted by scientists employed by the Federal government – Physicians, scientists, nurses, social workers, etc. – Clinical Trials conducted on NIH main campus Extramural clinical trials – Conducted by scientists who have been awarded grants through the NIH grant program – Clinical trials conducted around the U.S. and in some foreign countries

NIH Clinical Center in Bethesda, MD NCI’s Center for Cancer Research (CCR)

NCI’s CCR Clinical Trials Of these treatment trials, breakdown by Phase

NCI-Designated Cancer Centers Program Division of Cancer Treatment & Diagnosis –Cancer Therapy Evaluation Program (CTEP) Clinical Trials Cooperative Group Program –Cancer Imaging Program American College of Radiology Imaging Network (ACRIN) Division of Cancer Prevention –Community Clinical Oncology Program (CCOP) –Minority-Based CCOP NCI-Sponsored Clinical Trials: Extramural

NCI Designated Cancer Centers Program Research areas Basic research Clinical research Prevention, Control, Population/Behavioral Sciences Comprehensive Cancer Centers (39) Integrates research activities across all 3 major areas Cancer Centers (24) Scientific agenda focuses on any one or two research areas Total Centers (63)

NCI-Designated Cancer Centers Program Division of Cancer Treatment & Diagnosis – Cancer Therapy Evaluation Program (CTEP) Clinical Trials Cooperative Group Program –Cancer Imaging Program American College of Radiology Imaging Network (ACRIN) Division of Cancer Prevention –Community Clinical Oncology Program (CCOP) –Minority-Based CCOP NCI-Sponsored Clinical Trials: Extramural

Currently sponsors over 140 INDsCurrently sponsors over 140 INDs Approx. 11,000 registered investigators at over 3,300 institutionsApprox. 11,000 registered investigators at over 3,300 institutions Over 1000 active protocolsOver 1000 active protocols 500 new protocols/year500 new protocols/year Approx. 33,000 patients accrued/yearApprox. 33,000 patients accrued/year Over 80 collaborative agreements (CRADAs, CTAs, and CSAs) with pharmaceutical companiesOver 80 collaborative agreements (CRADAs, CTAs, and CSAs) with pharmaceutical companies CTEP by Numbers

Cooperative Group Program (the “Groups”) is distinctive among NIH-supported clinical trials programs: –A clinical trials infrastructure that is continuously available to test new therapeutic strategies –Consists of researchers at institutions affiliated with the Groups who jointly develop and conduct trials in multi-institutional settings –Flexible research agenda allows change of strategy in response to changing scientific opportunities and new discoveries NCI-Sponsored Clinical Trials Cooperative Groups

NCI Cooperative Groups 10 Groups - 9 adult and 1 pediatric Multimodality: Cancer and Acute Leukemia Group B (CALGB) Eastern Cooperative Oncology Group (ECOG) North Central Cancer Treatment Group (NCCTG) Southwest Oncology Group (SWOG) NCI of Canada – Clinical Trials Group (NCIC-CTG)** Specialty: American College of Surgeons Oncology Group (ACOSOG) National Surgical Adjuvant Breast & Bowel Project (NSABP) Gynecologic Oncology Group (GOG) Radiation Therapy Oncology Group (RTOG) Children’s Oncology Group (COG) ** NCIC-CTG funding limited to participation in Intergroup trials

Scope United States and Canada –International Sites of US Groups Phase 3 adult cancer tx trials –Breast, GI, GU, GYN, Head & Neck, Leukemia, Lung, Lymphoma, Sarcoma, others Selected Phase 2 adult cancer tx trials Over 65 active trials for adults with cancer Over 22,000 enrollments since

CTSU Cumulative Accrual by Study: As of May 31, 2007 – Top 14 Trials in Accrual (* = Metastatic Trial) Trial #TitleSite NCIC-MA.27 Exemestane vs Anastrozole Breast CALGB CA (4 vs 6 cycles) vs Paclitaxel (4 vs 6 cycles) Breast NSABP-B-39 Whole Breast Irradiation vs Partial Breast Irradiation Breast NSABP-B-38 TAC vs DD AC-P vs DD AC-PG Breast N0147 mFOLFOX6 vs mFOLFOX6 + Cetuximab Colon PACCT1 TailoRx (Onco-Type DX) Breast NSABP-B-35 Anastrozole vs Tamoxifen in DCIS Breast S0221 Contin. AC+G vs Q 2 wk AC->P (Q 2 vs Q 12 wks) Breast IBCSG Role of Exemestane Plus GnRH Analogue Breast IBCSG Role of Ovarian Function Suppression & Exemestane Breast NSABP-C-08 mFOLFOX6 vs mFOLFOX6 + Bevacizumab Colon C80405 Chemo/BV vs Chemo/C225 vs Chemo/BV/C225 *CRC NSABP-B-30 AC  T vs AC vs ACT Breast ACOSOG-Z9001 Imatinib vs Placebo GIST

What types of trials? Focus on developing treatment approaches Integrate new agents into standard regimens Compare two or more novel approaches to an accepted standard Multimodality treatments Emphasis on incorporating correlative sciences, banking tissues and quality of life Uncommon diseases or less common presentations of common diseases

Selected NCI/CTEP-sponsored Group Trials Contributing to FDA-approved Indications for New Oncology Agents 1991 –Fludarabine phosphate (SWOG) –Pentostatin (CALGB, SWOG) 1992 –Paclitaxel (GOG, CALGB, ECOG, NCCTG, SWOG) 1993 –Melphalan IV (CALGB) 1994 –Pegaspargase (POG) 2001 –Imatinib mesylate (COG, SWOG) 2004 –Letrozole (NCIC, Intergroup) –Oxaliplatin (NCCTG, Intergroup); –Taxotere (SWOG) 2005 – Nelarabine (COG, CALGB) 2006 –Bevacizumab (ECOG, Intergroup); Rituxin (ECOG, Intergroup) –Herceptin (NSABP, NCCTG, Intergroup)

NCI-Designated Cancer Centers Program Division of Cancer Treatment & Diagnosis –Cancer Therapy Evaluation Program (CTEP) Clinical Trials Cooperative Group Program –Cancer Imaging Program American College of Radiology Imaging Network (ACRIN) Division of Cancer Prevention – Community Clinical Oncology Program (CCOP) – Minority-Based CCOP NCI-Sponsored Clinical Trials: Extramural

Parts of the CCOP Program CCOPMB-CCOPResearch Base Consortia of Hospitals & Practices that accrue patients to NCI trials Institutions with >40% minority cancer patients that accrue to trials Cooperative Groups Cancer Centers Design & conduct cancer control & prevention clinical trials

Community Clinical Oncology Program Participating Physicians (3,385) – 2,170 Physicians Accrue Trial Participants – 1,215 Physicians Refer Trial Participants Participating Hospitals (395)

Community Clinical Oncology Program Impact of CCOP Participation in Treatment – 122,910 Patients on Treatment Clinical Trials – 1/3 Accrual to Cooperative Group Treatment Trials – Results from Treatment Trials are Directly Applicable to Patients in Their Communities – Community Physicians Who Participate in Trials More Rapidly Adopt State-of-the-Art Treatment

Community Clinical Oncology Program Impact in Prevention – Over 93,380 Persons at Risk for Cancer on Prevention Clinical Trials – CCOP Network Is the Vehicle to Conduct Phase III Cancer Prevention Trials (all of which are peer reviewed) – Community Physicians Practices Are the Forefront for Cancer Prevention

NCCCP: Clinical Trials Key Components Types of Clinical Trials –Treatment –Cancer Control and Symptom Reduction –Prevention Complexity of Trials –Phase 2 and 3 –Multimodality capacity (i.e., RT+ surgery) –Ability to do translational type trials (specimen submission-rich) Connections to the Community –Ca Ctrs, Academic Ctrs, CCOP/MBCCOPs, Coop Groups, Industry –Referrals for phase 1 –Emphasis on Minority Accrual

NCCCP: Clinical Trials Components Area Clinical Trial Component 1. Community Input Local advisory board to advise & assist pilot w/ varied membership, assist to increase awareness of importance of CTs 2. Types of Trials Types include treatment, prevention, cancer control & symptom amelioration 3. Trial Complexity Trial complexity: multimodality, phase 2, translational trials, referral to phase I ctrs 4. CT Infrastructure Infrastructure & staff dedicated to working on clinical trials, education for new staff 5. Protocol Activation Timeliness Track protocol receipt to activation, develop a log to measure timelines

NCCCP: Clinical Trials Components 6. Collaborations Collaborations w/ Ca Ctrs, CCOPs, Groups, Academia, Industry 7. Outreach to the Underserved Programs and outreach for minorities & underserved to participate in trials 8. Accrual Tracking Track patient accrual to trials and keep log of reasons why or why not pts go or don't go on trials 9. Communication System of communication of clinical trial availability: internal and external AreaClinical Trial Component

NCCCP Research Questions: Reducing Barriers to Clinical Trial Participation Ineligibility by disease, trial type, common cross-trial factors, gender, others Minority accrual issues – barriers, new research issues from the community Physician participation – reasons some docs don’t participate, don’t randomize, won’t refer CIRB utilization – if yes, how is it working? – and if no, why? Phase 2 studies – problems & solutions